Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synsam ABOSTO:SYNSAM -0.18%85 ROE % is 20.79% as of Mar. 2026, which is 60% above its 10-year median of 12.96. GuruFocus rates OSTO:SYNSAM with a GF Score™ of 85/100 and a GF Value™ of kr61.30 (Fairly Valued). The stock has 1 warning sign investors should review. Among 799 Medical Devices & Instruments companies, Synsam AB ranks better than 92.49% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Synsam AB's annualized net income for the quarter that ended in Mar. 2026 was kr524 Mil. Synsam AB's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was kr2,521 Mil. Therefore, Synsam AB's annualized ROE % for the quarter that ended in Mar. 2026 was 20.79%.
The historical rank and industry rank for Synsam AB's ROE % or its related term are showing as below:
OSTO:SYNSAM'
s ROE % Range Over the Past 10 Years
Min: 11.28 Med: 12.96 Max: 20.14
Current: 20.14
During the past 8 years, Synsam AB's highest ROE % was 20.14%. The lowest was 11.28%. And the median was 12.96%.
OSTO:SYNSAM's ROE % is ranked better than 92.49% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs OSTO:SYNSAM: 20.14
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Synsam AB ROE % Related Terms
Synsam AB ROE % Historical Data
* Premium members only.
The historical data trend for Synsam AB's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Synsam AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synsam AB ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Synsam AB's ROE % distribution charts can be found below:
* The bar in red indicates where Synsam AB's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Synsam AB (OSTO:SYNSAM) has a ROE % of 20.79% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Synsam AB and its competitors. This is 60% above median its historical median of 12.96. Over the past decade, Synsam AB's ROE % has ranged from 11.28 to 20.14. According to the industry distribution chart, Synsam AB ranks #60 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 7.5%.
Is Synsam AB's ROE % too high?
Synsam AB's current ROE % of 20.79% is 60% above median its 10-year median of 12.96. Over the past 10 years, this metric has ranged from a low of 11.28 to a high of 20.14. The Medical Devices & Instruments industry median ROE % is 2.42. Synsam AB's value of 20.79% is 759.1% above this industry median. Based on the distribution chart, Synsam AB ranks #60 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Synsam AB has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Synsam AB's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Synsam AB ranks #60 out of 799 companies for ROE %. This places Synsam AB in the top 8% of its industry — outperforming the majority of peers. The industry median ROE % is 2.42. Synsam AB's value of 20.79% is 759.1% above this benchmark. Historically, Synsam AB's own ROE % has ranged from 11.28 to 20.14 over the past decade. While the company's 10-year median is 12.96 vs. the industry median of 2.42, Synsam AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synsam AB's current ROE % of 20.79% is 759.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Synsam AB and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synsam AB's current ROE % is 20.79%, which is 60% above median its own 10-year median of 12.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synsam AB stock overvalued right now?
Based on GuruFocus' analysis, Synsam AB (OSTO:SYNSAM) is currently considered Fairly Valued. The stock's GF Value™ is kr61.30, compared to a current price of kr56.50 — trading 7.8% below its estimated fair value. The current ROE % is 20.79%, which is 60% above median its 10-year median of 12.96 and 759.1% above the Medical Devices & Instruments industry median of 2.42. Synsam AB's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Synsam AB (OSTO:SYNSAM), the current ROE % is 20.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synsam AB (OSTO:SYNSAM) Overvalued in 2026?
Based on GuruFocus' analysis, Synsam AB stock appears to be undervalued.
The current stock price of kr56.50 is trading 7.8% below its estimated GF Value™ of kr61.30.
GuruFocus considers Synsam AB to be Fairly Valued.
Key valuation signals for OSTO:SYNSAM:
ROE %: 20.79% (60% above median its 10-year median of 12.96)
GF Value™: kr61.30 vs. price of kr56.50 (7.8% below fair value)
Industry Position: 759.1% above the Medical Devices & Instruments median (#60 of 799)
No single metric tells the full story. See the OSTO:SYNSAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synsam AB is a lifestyle company in optics and eye health in the Nordic region. The company offers various products and services in physical and digital stores, such as eye examinations, spectacles, sunglasses, sports spectacles, contact lenses, and accessories in optical retail, as well as spectacles subscriptions and related services under the name Synsam Lifestyle. Its stores are operated under the Synsam brand in Sweden, Norway, and Finland, and under the Profil Optik brand in Denmark and Iceland. The company comprises four segments: Sweden, which generates key revenue, Denmark, Norway, and Finland.
85GF Score
Get the complete analysis for OSTO:SYNSAM
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SYNSAM has been successfully added to your 
